閉経後の骨粗鬆症治療の世界市場

閉経後の骨粗鬆症治療の世界市場は2030年までに124億米ドルに達する見込み

2024年に98億米ドルと推定される閉経後の骨粗鬆症治療の世界市場は、2024～2030年の分析期間にCAGR 4.0%で成長し、2030年には124億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるビスフォスフォネートは、CAGR 5.2%を記録し、分析期間終了時には35億米ドルに達すると予測されます。ビタミンD3分野の成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は27億米ドルと推定、中国はCAGR 7.5％で成長予測

米国の閉経後の骨粗鬆症治療市場は、2024年には27億米ドルになると推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 7.5%で推移し、2030年には25億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.1%と予測されています。欧州では、ドイツがCAGR 2.3%で成長すると予測されています。

世界の閉経後の骨粗鬆症治療市場- 主要動向と促進要因のまとめ

閉経後の骨粗鬆症治療はなぜ高齢化社会に不可欠なのか？

閉経後骨粗鬆症（PMO）は、閉経後のエストロゲン欠乏により世界中で数百万人の女性が罹患する進行性の骨疾患であり、骨の脆弱性と骨折リスクの増大につながります。人口の高齢化と平均寿命の延長に伴い、閉経後骨粗鬆症は、特に北米、欧州、アジア太平洋地域において、公衆衛生上の大きな問題となっています。この疾患は運動能力、自立性、ヘルスケアコストに大きな影響を与えるため、効果的で革新的な骨粗鬆症治療に対する需要が高まっています。

骨粗鬆症に関連した骨折、特に股関節、脊椎、手首の骨折の有病率の増加により、早期診断、予防、治療が重視されるようになりました。骨の健康と骨折予防に対する意識が高まるにつれ、薬理療法、生活習慣の改善、高度な骨健康モニタリング技術による医学的介入を求める女性が増えています。閉経後骨粗鬆症治療市場は、検診プログラムの改善、政府のヘルスケア・イニシアチブ、医薬品開発の進歩により拡大しています。

技術の進歩は骨粗鬆症治療の選択肢をどのように改善しているか？

薬理学、バイオテクノロジー、デジタルヘルスソリューションにおける技術革新は、閉経後骨粗鬆症の管理を一変させ、治療をより効果的、個別化、便利にしています。最も重要な進歩の一つは、モノクローナル抗体、選択的エストロゲン受容体モジュレーター（SERM）、骨形成剤を含む次世代の骨粗鬆症治療薬の開発であり、これらはより優れた骨折予防と患者のアドヒアランスを向上させます。

中でも、デノスマブ（プロリア）やロモソズマブ（イブニティ）などのモノクローナル抗体療法は、骨吸収の標的化阻害と骨形成の促進をもたらし、治療の展望を変えつつあります。これらの生物学的製剤は、従来のビスフォスフォネート製剤に比べて優れた有効性を示し、注射による簡便な投与スケジュールで椎体骨折や非椎体骨折のリスクを軽減します。同様に、テリパラチド（Forteo）やアバロパラチド（Tymlos）のような同化薬の開発により、骨再生の促進を必要とする高リスク患者に対する新たな治療選択肢が導入されました。

デジタルヘルスやウェアラブル技術の台頭も骨粗鬆症管理に革命をもたらしています。骨密度追跡アプリ、AI主導の骨折リスク評価ツール、遠隔患者モニタリングシステムなどのスマート健康モニタリング機器は、医師がリアルタイムの骨健康データに基づいて個別化された治療計画を立てるのに役立っています。さらに、遠隔医療やバーチャル診察は、特に農村部や十分なサービスを受けていない地域の高齢患者にとって、骨粗鬆症治療をより身近なものにしています。

閉経後の骨粗鬆症治療の成長を促進する市場動向とは？

閉経後の骨粗鬆症治療市場で最も顕著な動向の一つは、生物学的製剤と標的療法の採用が増加していることです。ビスフォスフォネートの長期使用や、非定型骨折や顎骨壊死（ONJ）などの潜在的なリスクに対する懸念が高まる中、多くの医療提供者は患者を優れた安全性プロファイルを持つ新規の生物学的製剤治療に移行させています。このシフトは、モノクローナル抗体と蛋白同化薬の分野で力強い市場成長を促しています。

骨粗鬆症診断における人工知能（AI）と機械学習（ML）の統合は、市場に影響を与えるもう1つの主要動向です。AIを活用した骨の健康スクリーニング・アルゴリズムと予測分析は、骨密度（BMD）スキャン、遺伝子マーカー、患者のライフスタイル・データを分析することにより、骨粗鬆症の早期発見を可能にしています。この進歩により、積極的な治療開始と個別化された治療調整が促進され、患者の転帰とアドヒアランス率が向上しています。

もう一つの重要な動向は、併用療法とマルチターゲット治療戦略の重視です。調査チームは、骨吸収抑制と骨形成促進の両方を強化し、単剤療法よりも骨折予防効果を高める新しい薬剤の組み合わせを模索しています。さらに、薬理学的治療とともに、ビタミンDとカルシウムのサプリメントの使用が増加しており、治療効果と患者のコンプライアンスが向上しています。

骨粗鬆症啓蒙プログラムや政府のヘルスケア政策の拡大も市場の成長を形成しています。多くの国で、骨折リエゾン・サービス（FLS）や骨粗鬆症スクリーニング・プログラムが実施され、リスクのある女性の早期発見と治療が行われています。骨粗鬆症治療薬や骨の健康診断に対する償還政策や保険適用拡大は、さらに高い治療導入率を促しています。

閉経後の骨粗鬆症治療市場の成長を促進する要因は？

閉経後の骨粗鬆症治療市場の成長は、世界人口の高齢化、骨折発生率の上昇、薬物療法の進歩など、いくつかの要因によってもたらされます。特に、日本、中国、米国、欧州など、人口動態の高齢化が急速に進んでいる地域では、閉経後女性の数が世界的に増加していることが主な要因の1つです。50歳以上の女性の3人に1人が骨粗鬆症に関連した骨折に苦しむと推定されており、予防的・治療的介入に対する需要は加速しています。

もう一つの大きな成長要因は、骨粗鬆症治療薬の研究開発（R&D）の拡大です。製薬会社は、二重作用治療薬、幹細胞を用いた骨再生治療薬、より少ない副作用でより高い効果が期待できる遺伝子標的治療薬など、新世代の骨粗鬆症治療薬に多額の投資を行っています。骨粗鬆症治療にバイオシミラーが導入されたことで、先進的な治療がより手頃な価格で利用できるようになり、新興経済諸国での市場開拓が進んでいます。

骨粗鬆症管理のためのデジタルヘルスソリューションの採用が増加していることも、市場拡大に寄与しています。モバイルヘルス（mヘルス）アプリ、ウェアラブル骨密度モニター、AI主導のリスク評価ツールが利用可能になったことで、患者や医師は骨粗鬆症をより効果的に追跡・管理できるようになっています。さらに、遠隔医療サービスと遠隔患者モニタリング・プログラムは、特にヘルスケア・インフラが限られている地域において、骨粗鬆症治療をより身近なものにしています。

最後に、骨粗鬆症の予防と生活習慣への介入に対する意識の高まりが、早期治療の導入を促進しています。体重を支える運動、栄養補給、生活習慣の改善を推進する公衆衛生キャンペーンは、女性に早期の骨粗鬆症検診と予防治療を受けるよう促しています。骨粗鬆症が深刻な慢性疾患であるという認識が広まるにつれ、ヘルスケアプロバイダーは予防的な骨の健康管理を優先するようになり、骨粗鬆症治療に対する長期的な需要を押し上げています。

骨粗鬆症の負担が増加し続ける中、生物学的製剤の進歩、デジタルヘルスの革新、骨折予防と早期介入に向けた世界の取り組みによって、閉経後の骨粗鬆症治療市場の拡大が見込まれています。

セグメント

治療タイプ（ビスフォスフォネート、ビタミンD3、エストロゲン作動薬／拮抗薬、ホルモン補充療法、副甲状腺ホルモン療法、その他の治療タイプ）、流通チャネル（病院薬局、小売薬局、その他の流通チャネル）

調査対象企業の例

• Allergan plc
• Amgen Inc.
• Cipla Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Entera Bio Ltd.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Radius Health, Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Postmenopausal Osteoporosis Treatment Market to Reach US$12.4 Billion by 2030

The global market for Postmenopausal Osteoporosis Treatment estimated at US$9.8 Billion in the year 2024, is expected to reach US$12.4 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Vitamin D3 segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 7.5% CAGR

The Postmenopausal Osteoporosis Treatment market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Postmenopausal Osteoporosis Treatment Market - Key Trends & Drivers Summarized

Why Is Postmenopausal Osteoporosis Treatment Essential for Aging Populations?

Postmenopausal osteoporosis (PMO) is a progressive bone disease that affects millions of women worldwide due to estrogen deficiency following menopause, leading to increased bone fragility and fracture risk. With aging populations and longer life expectancy, postmenopausal osteoporosis has become a major public health concern, particularly in North America, Europe, and Asia-Pacific, where a rising number of postmenopausal women are at risk of osteoporotic fractures. The condition significantly impacts mobility, independence, and healthcare costs, driving the demand for effective and innovative osteoporosis treatments.

The increasing prevalence of osteoporosis-related fractures, especially hip, spine, and wrist fractures, has led to a greater focus on early diagnosis, prevention, and treatment. As awareness of bone health and fracture prevention grows, more women are seeking medical intervention through pharmacological therapies, lifestyle modifications, and advanced bone health monitoring technologies. The market for postmenopausal osteoporosis treatments is expanding due to improved screening programs, government healthcare initiatives, and advancements in drug development.

How Are Technological Advancements Improving Osteoporosis Treatment Options?

Innovations in pharmacology, biotechnology, and digital health solutions are transforming the management of postmenopausal osteoporosis, making treatments more effective, personalized, and convenient. One of the most significant advancements is the development of next-generation osteoporosis drugs, including monoclonal antibodies, selective estrogen receptor modulators (SERMs), and bone-forming agents that offer better fracture protection and improved patient adherence.

Among the latest breakthroughs, monoclonal antibody therapies such as Denosumab (Prolia) and Romosozumab (Evenity) are changing the treatment landscape by providing targeted inhibition of bone resorption and enhanced bone formation. These biologic agents offer superior efficacy compared to traditional bisphosphonates, reducing the risk of vertebral and non-vertebral fractures with convenient injection-based dosing schedules. Similarly, the development of anabolic agents like Teriparatide (Forteo) and Abaloparatide (Tymlos) has introduced new treatment options for high-risk patients requiring accelerated bone regeneration.

The rise of digital health and wearable technology is also revolutionizing osteoporosis management. Smart health monitoring devices, including bone density tracking apps, AI-driven fracture risk assessment tools, and remote patient monitoring systems, are helping physicians tailor personalized treatment plans based on real-time bone health data. Additionally, telemedicine and virtual consultations are making osteoporosis care more accessible, particularly for elderly patients in rural and underserved regions.

What Market Trends Are Driving the Growth of Postmenopausal Osteoporosis Treatment?

One of the most prominent trends in the postmenopausal osteoporosis treatment market is the increasing adoption of biologics and targeted therapies. With growing concerns about long-term bisphosphonate use and its potential risks, such as atypical fractures and osteonecrosis of the jaw (ONJ), many healthcare providers are transitioning patients to novel biologic treatments with superior safety profiles. This shift is driving strong market growth in the monoclonal antibody and anabolic drug segments.

The integration of artificial intelligence (AI) and machine learning (ML) in osteoporosis diagnostics is another key trend influencing the market. AI-powered bone health screening algorithms and predictive analytics are enabling early detection of osteoporosis by analyzing bone mineral density (BMD) scans, genetic markers, and patient lifestyle data. This advancement is facilitating proactive treatment initiation and personalized therapy adjustments, improving patient outcomes and adherence rates.

Another significant trend is the emphasis on combination therapies and multi-target treatment strategies. Researchers are exploring new drug combinations that enhance both bone resorption inhibition and bone formation stimulation, offering greater fracture protection than monotherapy. Additionally, the increasing use of vitamin D and calcium supplementation, along with pharmacological treatments, is improving treatment effectiveness and patient compliance.

The expansion of osteoporosis awareness programs and government healthcare policies is also shaping market growth. Many countries are implementing fracture liaison services (FLS) and osteoporosis screening programs to ensure early detection and treatment of at-risk women. Reimbursement policies and insurance coverage expansions for osteoporosis medications and bone health screenings are further encouraging higher treatment adoption rates.

What Factors Are Driving the Growth of the Postmenopausal Osteoporosis Treatment Market?

The growth in the postmenopausal osteoporosis treatment market is driven by several factors, including an aging global population, rising fracture incidence, and advancements in drug therapies. One of the primary drivers is the growing number of postmenopausal women worldwide, particularly in regions with rapidly aging demographics, such as Japan, China, the U.S., and Europe. With one in three women over the age of 50 estimated to suffer from an osteoporosis-related fracture, the demand for preventive and therapeutic interventions is accelerating.

Another major growth factor is the expansion of research and development (R&D) in osteoporosis drug discovery. Pharmaceutical companies are heavily investing in new-generation osteoporosis drugs, including dual-action therapies, stem cell-based bone regeneration treatments, and gene-targeted medications that promise higher efficacy with fewer side effects. The introduction of biosimilars for osteoporosis treatments is also making advanced therapies more affordable and accessible, increasing market penetration in developing economies.

The rising adoption of digital health solutions for osteoporosis management is contributing to market expansion. The availability of mobile health (mHealth) apps, wearable bone density monitors, and AI-driven risk assessment tools is empowering patients and physicians to track and manage osteoporosis more effectively. Additionally, telehealth services and remote patient monitoring programs are making osteoporosis care more accessible, particularly in regions with limited healthcare infrastructure.

Lastly, the increasing awareness of osteoporosis prevention and lifestyle interventions is driving early treatment adoption. Public health campaigns promoting weight-bearing exercises, nutritional supplementation, and lifestyle modifications are encouraging women to seek early osteoporosis screenings and preventive treatments. With the growing recognition of osteoporosis as a serious chronic condition, healthcare providers are prioritizing proactive bone health management, boosting long-term demand for osteoporosis therapies.

As the burden of osteoporosis continues to rise, the postmenopausal osteoporosis treatment market is expected to expand, driven by biologic drug advancements, digital health innovations, and global initiatives for fracture prevention and early intervention.

SCOPE OF STUDY:

The report analyzes the Postmenopausal Osteoporosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Other Treatment Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Allergan plc
• Amgen Inc.
• Cipla Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Entera Bio Ltd.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Radius Health, Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Postmenopausal Osteoporosis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Postmenopausal Osteoporosis Spurring Demand for Advanced Treatment Options
  • Increasing Awareness of Osteoporosis Among Women Drives the Adoption of Preventive Care and Treatment Solutions
  • Growth in the Elderly Population Intensifies the Need for Effective Postmenopausal Osteoporosis Therapies
  • Shift Towards Personalized Medicine Expands Opportunities for Tailored Postmenopausal Osteoporosis Treatments
  • Increased Investment in Research and Development Accelerates Innovation in Postmenopausal Osteoporosis Treatment
  • Emergence of New Drug Classifications, Such as Monoclonal Antibodies, Expands Treatment Options
  • Demand for Injectable Medications for Postmenopausal Osteoporosis Spurs Market Expansion
  • Regulatory Approval of New Therapies and Treatment Modalities Accelerates the Market Growth
  • Advances in Bone Mineral Density Monitoring Technology Strengthen Market Penetration of Postmenopausal Osteoporosis Treatments
  • Rising Healthcare Expenditure in Developing Markets Increases Access to Osteoporosis Treatment Solutions
  • Growing Popularity of Combination Therapies Offers New Growth Opportunities for Treatment Providers
  • Increasing Preference for Non-Surgical Treatment Solutions Enhances the Market for Postmenopausal Osteoporosis Drugs
  • Innovations in Delivery Systems, Such as Oral and Subcutaneous Therapies, Strengthen the Business Case for New Treatments
  • Integration of Digital Health Tools in Osteoporosis Care Generates New Pathways for Disease Management and Monitoring
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Postmenopausal Osteoporosis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Vitamin D3 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Vitamin D3 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Vitamin D3 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Estrogen Agonist / Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Estrogen Agonist / Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Estrogen Agonist / Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hormone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Hormone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Parathyroid Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• JAPAN
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• CHINA
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: China 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• EUROPE
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• FRANCE
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 65: France Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: France 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 68: France Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: France 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• GERMANY
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Germany 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Germany 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Italy 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Italy 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 83: UK Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: UK 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 86: UK Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: UK 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Spain 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Spain 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Russia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Russia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Australia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Australia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• INDIA
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 122: India Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: India 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 125: India Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: India 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: South Korea 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: South Korea 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Argentina 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Argentina 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Brazil 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Brazil 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Mexico 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Mexico 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Iran 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Iran 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Israel 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Israel 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: UAE 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: UAE 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• AFRICA
  • Postmenopausal Osteoporosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Postmenopausal Osteoporosis Treatment by Treatment Type - Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Africa 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Postmenopausal Osteoporosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Africa 15-Year Perspective for Postmenopausal Osteoporosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION